ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 602

Individualised Infliximab Treatment: A Treatment Strategy Based on Therapeutic Drug Monitoring

Silje Watterdal Syversen1, Guro Løvik Goll1, Kristin Kaasen Jørgensen2, Johanna Gehin3, Cato Mork4, Tore Kvien5, Jorgen Jahnsen6, Nils Bolstad3 and Espen A. Haavardsholm5, 1Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, 2Dept Gastroenterology, Akershus University Hospital, Lørenskog, Norway, 3Medical Biochemistry, Oslo University Hospital, Oslo, Norway, 4None, Oslo, Norway, 5Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, 6Dept of Gastroenterology, Akershus University Hospital, Lørenskog, Norway

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: infliximab

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, October 21, 2018

Session Title: Rheumatoid Arthritis – Treatments Poster I: Strategy and Epidemiology

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose:

The purpose is to develop an individualised treatment strategy based on Therapeutic drug monitoring (TDM) in order to optimise efficacy of Infliximab (INX) treatment. Targeted therapies have greatly improved the treatment of patients inflammatory joint diseases, but a significant proportion of patients either do not respond sufficiently to therapy or loose efficacy over time. An extensive individual variation in serum drug concentrations suggests both under- and overtreatment of a substantial proportion of patients. Many patients develop anti-drug antibodies (ADAb) during therapy, contributing to reduced drug levels, inefficacy and adverse events. TDM can probably increase effectiveness of treatment with INX and other biological drugs.

Methods:

The treatment strategy has been developed by the steering committee of the NORwegian DRUg Monitoring study (NOR-DRUM), based on a systematic literature research (SLR), unpublished data and expert opinion. A SLR was performed in May 2016. In Norway neutralising ADAb are measured with an “in house” assay. For this assay, ADAb levels >50 µg/L are defined as “high”. This cut-off is based on own s-INX and ADAb data (Diakonhjemmet Hospital during 2015-2016) and clinical experience. The proposed strategy has been developed through a series of meetings in the project group consisting of national leading experts in this field (both clinicians experienced with TDM and laboratory physicians) and with additional input from international key experts in the scientific advisory board of the NOR-DRUM study.

Results:

The treatment strategy from infusion number 4 onwards is depicted in the Figure. The therapeutic range for serum INX (through levels) is defined as 3-8µg/ml (Figure, green zone). During the induction phase (infusion 1-3) the recommendation is to keep the level >20 µg/ml at infusion 2 and >15µg/ml at infusion 3. A guideline for action according to levels outside the therapeutic range is given in the Figure. If the patients develop high levels of ADAb the recommendation is to switch therapy.

Conclusion:

An individualised treatment strategy based on TDM has the potential to optimise therapy with infliximab and other biological drugs by; 1) prevention of treatment failure by identification of patients with drug levels below the therapeutic range, 2) reduction of overtreatment, which predispose to side effects and increase costs, and 3) early identification of ADAb development, with the possibility to detect treatment failures prior to a clinical flare and to prevent hypersensitivity reactions. The real life efficacy of this strategy is being investigated in an ongoing randomised clinical trial, NOR-DRUM (NCT03074656).


Disclosure: S. W. Syversen, None; G. L. Goll, AbbVie, Boeringer Ingelheim, Eli Lilly, Novartis, Pfizer, Orion Pharma, Roche, Sandoz, 5; K. K. Jørgensen, Tillots, Celltrion, Intercept, Sandoz, 5; J. Gehin, Roche, 5; C. Mork, None; T. Kvien, AbbVie, Biogen, BMS, Boehringer Ingelheim, Celgene, Celltrion, Eli Lilly, Epirus, Hospira, Merck-Serono, MSD, Mundipharma, Novartis, Oktal, Orion Pharma, Hospira/Pfizer, Roche, Sandoz and UCB, 5, 8,AbbVie, BMS, MSD, Pfizer, Roche, UCB., 2; J. Jahnsen, Orion Pharma, 5,Celltrion, 5,Janssen, 5,Pfizer, Inc., 5,MSD, 5,AbbVie Inc., 5,Takeda, 5,Napp Pharma, 5,Roche, 5,Boeringer Ingelheim, 5,Astro Pharma, 5,Mundi Pharma, 5,Sandoz, 5; N. Bolstad, None; E. A. Haavardsholm, Pfizer, Eli Lilly, Janssen-Cilag, Roche, Celegene, Pfizer, UCB, Roche, AbbVie, MSD, EliLilly, 5,Pfizer, UCB, Roche, MSD, AbbVie, 2.

To cite this abstract in AMA style:

Syversen SW, Goll GL, Jørgensen KK, Gehin J, Mork C, Kvien T, Jahnsen J, Bolstad N, Haavardsholm EA. Individualised Infliximab Treatment: A Treatment Strategy Based on Therapeutic Drug Monitoring [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/individualised-infliximab-treatment-a-treatment-strategy-based-on-therapeutic-drug-monitoring/. Accessed February 5, 2023.
  • Tweet
  • Email
  • Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/individualised-infliximab-treatment-a-treatment-strategy-based-on-therapeutic-drug-monitoring/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences